For the latest COVID information Click Here.
Approval is required to advertise surveys to the ARA Membership. The procedure for Surveys of the Membership can be found here. Please advise:
Please enclose a copy of the survey, the research protocol and ethics approval with your application and send to ara@rheumatology.org.au.
Click here to complete the survey.
Endocrinologists Prof Rory Clifton-Bligh and Dr Shejil Kumar are requesting your assistance with estimating the prevalence of X-linked hypophosphataemia (XLH) amongst adults in Australia and to characterise the Australian adult XLH cohort.
If you have managed any adult patients with XLH in the past ten years, then we invite you to complete this survey. The survey will ask questions about the patients' clinical course, complications and treatment. The survey takes approximately 15 minutes to complete per patient and your progress can be saved and returned to at a later time if needed. We acknowledge that completing this survey requires your time and we would really appreciate your contribution to this research.
The study has been approved by the local ethics committee (NSLHD) and results are securely stored on a REDCap database.
If you have any questions about the study, please feel free to contact Dr Shejil Kumar at shejil.kumar@health.nsw.gov.au.
Survey Closes: 31 November 2024
Date Posted: 9 October 2024
The purpose of this 5-minute survey is to establish an understanding of the knowledge and attitudes about cannabis by rheumatologists and those who care for people with rheumatic diseases from around the world. The survey will likely close April 30, 2024. Please contact Dr. Kaleb Michaud at rheumkap@ndb.org or call +1-316-263-2125 for more information or questions.
If you have questions about your rights as a research subject, you may contact Solutions IRB at +1-855-226-4472 or participants@solutionsirb.com.
Click here to read the privacy statement.
Survey Closes: 31 December 2024
Date Posted: 28 February 2024
Do you have patients on or ≥2 advanced immunosuppressive therapies (eg biological agents) concurrently that are not typically used in combination?
Researchers from the University of Sydney are looking to assess the important and emerging area of outcomes of these patients, via an online de-identified registry. All data is stored securely and in the strictest of confidence, and the study has been granted Human Research Ethics Committee approval.
Please follow this link for the database to fill out patient details or receive further details. The survey takes 5-10 minutes (per patient). Any clinician who fills ≥10 patients will be offered co-authorship on the academic output.
Many thanks in advance for your time
Dr John Chetwood (john.chetwood@health.nsw.gov.au) On behalf of the The Multiple Advanced Therapies Research Team
Survey Closes: 1 December 2024
Date Posted: 4 January 2024